Overview

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Status:
Terminated

Trial end date:
2016-04-06

Target enrollment:

Participant gender:

Summary

This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of cetuximab plus Irinotecan. A Japanese Lead in Cohort will assess the safety of the combination of PF-05212384 + irinotecan in patients enrolled at Japanese sites.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Camptothecin
Cetuximab
Gedatolisib
Irinotecan